bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid

11 Feb 2025 07:01 CET

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_1314247_PR_bioMrieux_BIOFIRE_GI_Panel_FDA_Clearance.pdf